Corium International Inc. (NASDAQ:CORI) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Friday.
According to Zacks, “Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. “
Other equities analysts have also issued reports about the company. FBR & Co set a $18.00 target price on Corium International and gave the stock a “buy” rating in a research note on Friday, August 5th. Leerink Swann set a $16.00 target price on Corium International and gave the stock a “buy” rating in a research note on Tuesday, November 22nd. Finally, Needham & Company LLC restated a “buy” rating and issued a $15.00 target price on shares of Corium International in a research note on Monday, September 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $12.25.
Corium International (NASDAQ:CORI) opened at 5.43 on Friday. The firm’s market capitalization is $120.58 million. The company has a 50 day moving average price of $5.02 and a 200-day moving average price of $4.76. Corium International has a 1-year low of $3.14 and a 1-year high of $9.93.
Institutional investors have recently made changes to their positions in the stock. Opaleye Management Inc. raised its position in shares of Corium International by 1.4% in the first quarter. Opaleye Management Inc. now owns 360,000 shares of the biopharmaceutical company’s stock valued at $1,390,000 after buying an additional 5,000 shares during the period. RTW Investments LLC raised its position in shares of Corium International by 3.0% in the second quarter. RTW Investments LLC now owns 852,961 shares of the biopharmaceutical company’s stock valued at $2,960,000 after buying an additional 24,629 shares during the period. Finally, Paloma Partners Management Co purchased a new position in shares of Corium International during the second quarter valued at approximately $152,000. Hedge funds and other institutional investors own 88.40% of the company’s stock.
About Corium International
Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.